ATE292689T1 - Verbesserte verfahren zur transfektion der t- zellen - Google Patents

Verbesserte verfahren zur transfektion der t- zellen

Info

Publication number
ATE292689T1
ATE292689T1 AT96913327T AT96913327T ATE292689T1 AT E292689 T1 ATE292689 T1 AT E292689T1 AT 96913327 T AT96913327 T AT 96913327T AT 96913327 T AT96913327 T AT 96913327T AT E292689 T1 ATE292689 T1 AT E292689T1
Authority
AT
Austria
Prior art keywords
cells
transfection
improved methods
gene
nucleic acid
Prior art date
Application number
AT96913327T
Other languages
English (en)
Inventor
Carl H June
Craig B Thompson
Suil Kim
Original Assignee
Us Navy
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/475,136 external-priority patent/US6692964B1/en
Application filed by Us Navy, Univ Michigan filed Critical Us Navy
Application granted granted Critical
Publication of ATE292689T1 publication Critical patent/ATE292689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96913327T 1995-05-04 1996-05-02 Verbesserte verfahren zur transfektion der t- zellen ATE292689T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43509595A 1995-05-04 1995-05-04
US08/475,136 US6692964B1 (en) 1995-05-04 1995-06-07 Methods for transfecting T cells
PCT/US1996/006200 WO1996034970A1 (en) 1995-05-04 1996-05-02 Improved methods for transfecting t cells

Publications (1)

Publication Number Publication Date
ATE292689T1 true ATE292689T1 (de) 2005-04-15

Family

ID=27030423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913327T ATE292689T1 (de) 1995-05-04 1996-05-02 Verbesserte verfahren zur transfektion der t- zellen

Country Status (7)

Country Link
US (1) US20060246587A1 (de)
EP (1) EP0824594B1 (de)
JP (3) JP4031033B2 (de)
AT (1) ATE292689T1 (de)
CA (1) CA2220226C (de)
DE (1) DE69634563T2 (de)
WO (1) WO1996034970A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907366D0 (en) * 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins
US7816134B2 (en) * 2000-08-16 2010-10-19 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic T cells
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
CN100510060C (zh) 2001-08-15 2009-07-08 宝生物工程株式会社 抗原特异性细胞毒性t细胞的扩大培养方法
ATE491021T1 (de) 2002-03-25 2010-12-15 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
DE602004025591D1 (de) 2003-08-22 2010-04-01 Takara Bio Inc Verfahren zur herstellung zytotoxischer lymphozyten
WO2005030251A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
WO2006101205A1 (ja) * 2005-03-25 2006-09-28 Kaneka Corporation Ｔ細胞の活性化方法及び活性化ｔ細胞製造用キット
CN101243187B (zh) 2005-08-17 2012-07-11 宝生物工程株式会社 淋巴细胞的制备方法
CA2623735A1 (en) * 2005-09-30 2007-04-12 Takara Bio Inc. Method for production of t cell population
EP3750993B1 (de) * 2014-07-11 2023-12-27 Celgene Corporation Verfahren zur verbesserung der vektortransduktionseffizienz in t-lymphozyten
WO2016168275A1 (en) * 2015-04-13 2016-10-20 Maxcyte, Inc. Methods and compositions for modifying genomic dna
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
WO1994012196A1 (en) * 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
CN1079830C (zh) * 1993-04-20 2002-02-27 索利斯治疗学公司 对受胞内传染原感染的个体进行治疗的方法和物质
EP1553168A3 (de) * 1993-06-04 2011-04-06 The United States of America as represented by The Secretary of The Navy Verfahren zur selektiven Stimulierung der T-Zellproliferation
FR2707091B1 (fr) * 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
JPH09500788A (ja) * 1993-07-26 1997-01-28 ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
CA2191586A1 (en) * 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5840576A (en) * 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
WO1996006942A1 (de) * 1994-08-31 1996-03-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetisch veränderte t-zellen
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells

Also Published As

Publication number Publication date
DE69634563D1 (de) 2005-05-12
JP2006109844A (ja) 2006-04-27
EP0824594A1 (de) 1998-02-25
EP0824594B1 (de) 2005-04-06
CA2220226A1 (en) 1996-11-07
DE69634563T2 (de) 2006-02-16
JPH11505419A (ja) 1999-05-21
JP4189007B2 (ja) 2008-12-03
US20060246587A1 (en) 2006-11-02
CA2220226C (en) 2008-10-21
JP4031033B2 (ja) 2008-01-09
WO1996034970A1 (en) 1996-11-07
JP2007125041A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
EP1586655A3 (de) Verbesserte Methoden zur Transfektion von T Zellen
ATE292689T1 (de) Verbesserte verfahren zur transfektion der t- zellen
ATE124725T1 (de) Verbessertes verfahren zur herstellung von faktor viii:c-typ-proteinen.
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
ES2059478T3 (es) Co-expresion en celulas eucarioticas.
ATE224457T1 (de) Verfahren zur identifizierung von nukleinsäuren, welche agenzien kodieren, die zelluläre phenotypen beeinflussen
EP1067949A4 (de) Sequenz und verfahren zur gentechnischen herstellung von proteinen mit zellmembran translozierender aktivität.
DE3785102D1 (de) Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
DE69633669D1 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
ES8401132A1 (es) Metodo de expresion de un gen codificador de un polipeptido util en una coagulacion de la leche.
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
ATE391175T1 (de) Multidrug resistenz gen
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
AU8110487A (en) DNA molecules coding for proteins targeted to plant cell walls
EP0201086A3 (en) Method of producing useful high-molecular-weight substances by culturing proliferous animal cells and culture system therefor
ATE309267T1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
DE3687948D1 (de) Verfahren und nukleinsaeure zur herstellung von lecithin: cholestrinacyltransferase.
DE69414477D1 (de) Verfahren zur zeitlichen Einteilung von zu Nachrichten gehörenden Zellemissionen sowie Vorrichtung zur Durchführung dieses Verfahrens
DK0706567T3 (da) Peptidfamilie betegnet xenoxiner
DE3673686D1 (de) Immobilisierte maltooligosaccharid-bildende amylase und verfahren zur herstellung von maltooligosaccharid unter verwendung des genannten enzyms.
DE3579733D1 (de) Verfahren zur trennung von tierischen zellen aus fluessiger kultur.
DE69616276D1 (de) Verfahren zur produktion von proteinen
DE60040864D1 (de) Verfahren zur selektiven isolierung einer nukleinsäure
ATA315485A (de) Verfahren zur herstellung von penetratoren fuer unterkalibrige wuchtgeschosse sowie huelle zur verwendung bei der durchfuehrung dieses verfahrens
DE69823813D1 (de) Malignitätsunterdrückung durch verwendung von ribonucleotid reductase r1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0824594

Country of ref document: EP